SPECIALTY QUANTITY LIMIT PROGRAM

XOSPATA (gilteritinib)

I. PROGRAM DESCRIPTION


The standard limit is designed to allow a quantity sufficient for the most common uses of the medication. The recommended dosing parameters for all FDA-approved indications fall within the standard limits. Coverage of an additional quantity may be reviewed on a case-by-case basis upon request.

II. COVERED QUANTITIES


Medication	Standard Limit	FDA-recommended dosing
Xospata (gilteritinib) 40 mg tablets	90 per 30 days	Acute Myeloid Leukemia (AML): 120 mg once daily Dose modification for toxicity: 80 mg once daily

III. REFERENCES

1. Xospata [package insert]. Northbrook, IL: Astellas Pharma Inc.; November 2018.



© 2018 CVS Caremark. All rights reserved.



This document contains confidential and proprietary information of CVS Caremark and cannot be reproduced, distributed or printed without written

